Riversedge Advisors LLC Invests $331,000 in AstraZeneca PLC (NASDAQ:AZN)

Riversedge Advisors LLC acquired a new position in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 4,502 shares of the company's stock, valued at approximately $331,000.

Other large investors also recently modified their holdings of the company. Banque Transatlantique SA bought a new position in shares of AstraZeneca in the 4th quarter worth $26,000. Confluence Investment Management LLC bought a new position in shares of AstraZeneca during the first quarter valued at about $27,000. Mascagni Wealth Management Inc. bought a new position in shares of AstraZeneca during the fourth quarter valued at about $29,000. FNY Investment Advisers LLC bought a new position in shares of AstraZeneca during the first quarter valued at about $29,000. Finally, Highline Wealth Partners LLC lifted its position in shares of AstraZeneca by 447.4% during the first quarter. Highline Wealth Partners LLC now owns 416 shares of the company's stock valued at $31,000 after purchasing an additional 340 shares in the last quarter. Institutional investors and hedge funds own 20.35% of the company's stock.

AstraZeneca Stock Performance

AZN traded down $0.68 during trading hours on Friday, hitting $71.13. The stock had a trading volume of 2,729,851 shares, compared to its average volume of 5,279,228. The company's fifty day simple moving average is $70.72 and its 200 day simple moving average is $70.81. AstraZeneca PLC has a 1 year low of $61.24 and a 1 year high of $87.68. The stock has a market cap of $220.60 billion, a PE ratio of 28.57, a price-to-earnings-growth ratio of 1.31 and a beta of 0.37. The company has a quick ratio of 0.70, a current ratio of 0.90 and a debt-to-equity ratio of 0.65.

AstraZeneca (NASDAQ:AZN - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The company reported $1.24 earnings per share for the quarter, topping the consensus estimate of $1.10 by $0.14. AstraZeneca had a return on equity of 33.14% and a net margin of 14.14%. The company had revenue of $13.59 billion during the quarter, compared to analyst estimates of $13.71 billion. During the same quarter last year, the firm posted $2.06 EPS. The firm's revenue for the quarter was up 7.2% on a year-over-year basis. Equities analysts anticipate that AstraZeneca PLC will post 4.51 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts recently weighed in on AZN shares. Berenberg Bank set a $97.00 price target on shares of AstraZeneca in a research report on Wednesday. BNP Paribas initiated coverage on AstraZeneca in a research note on Tuesday, April 15th. They set an "outperform" rating and a $75.00 target price on the stock. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $89.00.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.